Macrogen

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

Retrieved on: 
Monday, July 31, 2023
Telephone, Webcast, ID, Cancer, Macrogen, Therapy, Rare-earth element, Internet service provider, MD

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes on Wednesday, August 9, 2023.

Key Points: 
  • ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes on Wednesday, August 9, 2023.
  • MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, August 9, 2023, at 4:30 pm ET.
  • To participate via telephone, please register in advance via this link .
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Docetaxel, Prostate-specific antigen, Therapy, Half-life, Conference call, Telephone, Food and Drug Administration, Merkel-cell carcinoma, Cancer, Macrogen, RPF, ID, Sale, Trial of the century, Acute myeloid leukemia, Lung, ASCO, B7, Endometrial cancer, Patient, DRI, Syndrome, CD123, MCC, Webcast, ADC, Johns Hopkins, Cytokine release syndrome, Enoblituzumab, PD-1, FDA, Research, Conference, PSA, Food, Prostate cancer, D, Pharmaceutical industry, Vaccine, Medical imaging, Internet service provider, Cryptocurrency, Nature Medicine, Incyte, Sanofi

ET

Key Points: 
  • ET
    ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2023.
  • MacroGenics initiated the Phase 2 portion of the TAMARACK study of vobra duo in patients with mCRPC in late 2022.
  • MacroGenics anticipates commencement of enrollment under the revised protocol beginning in the second quarter of 2023 and expects to provide a clinical update in 2024.
  • R&D Expenses: Research and development expenses were $45.9 million for the quarter ended March 31, 2023, compared to $61.4 million for the quarter ended March 31, 2022.

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

Retrieved on: 
Thursday, May 4, 2023
Telephone, Webcast, ID, Cancer, Macrogen, Therapy, Pharmaceutical industry, Internet service provider, Security (finance), MD

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.

Key Points: 
  • ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.
  • MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 9, 2023, at 4:30 pm ET.
  • To participate via telephone, please register in advance via this link .
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
Kansai Medical University, University, Therapy, Senior, CRC, CFO, Cholangiocarcinoma, EVP, Macrogen, Emergent, G&A, MBA, Dartmouth College, DLL4, Doctor of Philosophy, Arbutus Biopharma, Audit committee, Eli Lilly, Stage 2, Key Stage 1, Margetuximab, Patient, M.B.A, Sprint Corporation, Compass, Cancer, Paclitaxel, CEB, Entrepreneurship, Merck, BTC, Treasurer, R, SVP, Pembrolizumab, Safety, NYSE, HCC, BA, Certified Treasury Professional, Nursing, Management, Pharmaceutical industry, Medical device, MD

Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC).

Key Points: 
  • Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC).
  • Initial data expected in the third quarter of 2023
    Expanded the management team with the appointment of Minori Rosales, M.D.
  • Initial results from this study are expected in the third quarter of 2023
    In April 2023, the company appointed Minori Rosales, MD PhD, as Senior Vice President & Head of Clinical Development.
  • Prior to Emergent BioSolutions, from 2009-2017, Mr. Lindahl was Chief Financial Officer at CEB, a NYSE-listed technology company.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, April 24, 2023
Therapy, Cancer, Macrogen, Virtual, Conference, MD

Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in a formal presentation on Wednesday, April 26, 2023, at 2:00 pm ET.

Key Points: 
  • Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in a formal presentation on Wednesday, April 26, 2023, at 2:00 pm ET.
  • MacroGenics’ management will also participate in one-on-one meetings.
  • Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 2, 2023, at 1:00 pm ET.
  • Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

CD276 Antibody Clinical Trials & Market Sales Forecasts, 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 29, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, CD276, Therapy, Survival, Indication, Macrogen, Trial of the century, Pharmacotherapy, Daiichi Sankyo, Biologics license application, Patient, AbbVie, DXD, ADC, Iodine, PD-1, FDA, BLA, Sarah Cannon Research Institute, Vaccine, Pharmaceutical industry, Fine chemical, Ipilimumab

The "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" report has been added to ResearchAndMarkets.com's offering.
  • Meanwhile, there are several drug candidates that have been steadily moving forward in their respective clinical trials hoping to be the first approved CD276 inhibitor.
  • Current leaders in the CD276 targeted checkpoint inhibitors include; Daiichi Sankyo, YmAb Therapeutics, AbbVie, BioAtla, Fate Therapeutics, MacroGenics, and several others.
  • Global CD276 Antibody Market Opportunity Assessment: > US$ 1 Billion
    Global CD276 Antibody Clinical Trials: > 30 Drugs In Trials
    CD276 Antibody Clinical Trials By Company, Indication & Phase

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

Retrieved on: 
Wednesday, March 22, 2023
Therapy, Merkel-cell carcinoma, Cancer, Macrogen, Patient, FDA, BLA, Food, Pharmaceutical industry, Incyte, MD

ZYNYZ, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), was previously developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.

Key Points: 
  • ZYNYZ, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), was previously developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.
  • “The FDA approval of ZYNYZ represents the third approval of a product originating from MacroGenics’ pipeline of proprietary or partnered product candidates,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics.
  • In addition, MacroGenics is eligible to receive tiered royalties of 15% to 24% on any global net sales of the product.
  • Finally, MacroGenics has an agreement with Incyte under which it manufactures a portion of Incyte’s global commercial supply of retifanlimab.

MacroGenics Provides Corporate Update and 2022 Financial Results

Retrieved on: 
Wednesday, March 15, 2023
Gilead Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, B7-H3, Cytokine release syndrome, ADC, New Board, ASCO, Clinical trial, Investigational New Drug, DRI, Cancer, Macrogen, Half-life, Telephone, Acute myeloid leukemia, CD123, Docetaxel, T1D, Sale, Syndrome, Webcast, RPF, Patient, PSA, Prostate-specific antigen, Parliamentary Information Technology Committee, FDA, ID, Conference call, Ageing, Gilead, D, Prostate cancer, B7, Research, Food, Therapy, IND, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Conference, Incyte

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2022.
  • MacroGenics initiated the Phase 2 portion of the TAMARACK study of vobra duo in patients with mCRPC in late 2022.
  • MacroGenics believes that removal of the control arm should allow the Company to provide a clinical update in 2024 potentially in support of a subsequent Phase 3 study in mCRPC.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.